ArticleDiscover oncology2025
Nomogram for predicting postoperative clinical remission of hypertension in patients with adrenal tumors.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveHypertension caused by adrenal tumors is a frequent cause of secondary hypertension. Treating primary adrenal disease can significantly improve or cure hypertension. However, hypertension may persist in some patients after surgery, leading to controversy over the choice of surgery or conservative treatment. The aim of this study is to construct and validate a model for predicting postoperative clinical remission of hypertension in patients with adrenal tumors to help surgeons make better surgical decisions. PATIENTS AND
methodsA retrospective analysis was conducted on data pertaining to 336 patients diagnosed with adrenal tumors and hypertension between January 1, 2012 and December 31, 2022. Potential predictor variables were utilized to develop a nomogram, which were internally validated using a bootstrap resampling method. Clinical data from 141 patients from January 1, 2023 to December 31, 2023 were analyzed for external validation using the same criteria.
resultsIn patients with non-functioning adrenal tumors, lower age, body mass index, and hypertension grade were considered independent predictors of postoperative clinical remission of hypertension. In patients with functional adrenal tumors, absence of diabetes mellitus, lower systolic blood pressure, and duration of hypertension were considered independent predictors of postoperative clinical remission of hypertension. The area under the curve (AUC) for the nonfunctional adrenal tumor prediction model was 0.761, the AUC for internal validation using the bootstrap method (resampling = 1000) was 0.757, and the AUC for the external validation cohort was 0.837. The AUC for the functional adrenal tumor prediction model was 0.848, the AUC for internal validation using the bootstrap method (resampling = 1000) was 0.836, and the AUC for the external validation cohort was 0.836. The calibration curves demonstrated a satisfactory fit between the model and clinical utility, as evidenced by the decision curve analysis.
conclusionNomograms have been demonstrated to perform well in predicting postoperative clinical remission of hypertension in patients with adrenal tumors. This may assist clinicians in distinguishing between patients with adrenal tumors who are likely to achieve clinical remission of hypertension after surgery at an early stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.